Abstract

Valsartan 4-mg/mL in SyrSpend SF pH4

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2021 - Volume 25, Number 4

Page(s): 329

Download in electronic PDF format for $75
  • Valsartan 4-mg/mL in SyrSpend SF pH4 Page 1

Abstract

A formulation for preparing Valsartan 4-mg/mL in SyrSpend SF pH4. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

  • formulation
  • valsartan
  • oral suspension
  • hypertension
  • high blood pressure
  • heart failure
  • left ventricular dysfunction
  • cardiac disorders
  • heart disease

Related Categories

  • FORMULATIONS
  • CARDIOLOGY
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2021
Pg. 329
Valsartan 4-mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Sep/Oct 2019
Pg. 412
Valsartan 4 mg/mL in Vehicle for Oral Solution USP
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 139
Valsartan 4 mg/mL in Syrup NF
Author(s): Allen Loyd V Jr
Mar/Apr 2019
Pg. 148
Captopril 0.8 mg/mL in SyrSpend SF Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2010
Pg. 108-111
Coenzyme Q10 Supplementation in the Treatment of Heart Disease
Author(s): Bramwell Bethany L
May/Jun 2008
Pg. 269
Valsartan 4-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
Jul/Aug 2021
Pg. 327
Nifedipine 4.mg/mL in SyrSpend SF pH4 Cherry Flavored
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 503
Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2019
Pg. 237
Valsartan 16-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2009
Pg. 367-371
Congestive Heart Failure and Other Medical Facts About Ferrets; Scout's Story: A Case Report on Treating Congestive Heart Failure in a Ferret
Author(s): Williams LaVonn A, Riley Kari
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
Mar/Apr 2005
Pg. 117-119
Combating Cardiovascular Disease With Compounded Medications. Part 1: Combination Cardiac Medicines to Control Blood Pressure
Author(s): Harrington Catherine A, Cauffield Jacintha
May/Jun 2006
Pg. 221
Enalapril Maleate 1-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2019
Pg. 147
Amlodipine 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Nov/Dec 2018
Pg. 494
Enalapril Maleate 1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2014
Pg. 169-174
Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Author(s): Zaid Abdel Naser, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
Sep/Oct 2021
Pg. 421
Spironolactone 2-mg/mL or 2-5.mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
May/Jun 2006
Pg. 220
Carvedilol 1.25-mg/mL Oral Suspension
Author(s): Allen Loyd V Jr
Jul/Aug 2018
Pg. 325
Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension
Author(s): Allen Loyd V Jr
May/Jun 2020
Pg. 229
Prednisolone 1 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr